Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

All Drugs and Chemicals

Amino Acids

Tyrosine Kinase Inhibitors

Tyrosine

Lorlatinib

Stéphanie Martinez, Dr

Frédéric BIGOT, Dr

Marie Capucine Willemin, Dr

Dorine TEMPLEMENT, Dr

Stanislas ROPERT, Dr

Nicolas CLOAREC, Dr

Sophie Schneider, Dr

Maéva ZYSMAN, Dr

Sophie COUSIN, Dr

Sigolène GALLAND, Dr

Coraline Dumenil, Dr

Jeannick MADELAINE, Dr

Patrick DUMONT, Dr

Philippe MASSON, Dr

Patrick MERLE, Dr

Lionel MOREAU

Isabelle Monnet, Dr

Laure FAVIER, dR

Denis MORO-SIBILOT

Olivier Molinier, Dr

Alexis Cortot, Pr

Aurélie Swalduz, Dr

Anne Madroszyk, Dr

Pascale Tomasini, Dr

Didier DEBIEUVRE, Dr

Marie Wislez, Pr

Jacques Cadranel, Pr

Jacques Cadranel, pr

Valérie Gounant, Dr

Marie-Ange MASSIANI, Dr

Michael Duruisseaux, Dr

Florian GUISIER, Dr

Céline Mascaux, Pr

Hélène Doubre, Dr

Audrey Rabeau, Dr

Delphine Carmier, Dr

Hélène MEYER, Dr

Aurélien BRINDEL, Dr

David Planchard, Dr

Denis Moro-Sibilot

Michael Duruisseaux

ROS1 rearrangements are present in 1-2% of NSCLC cases and define a distinct molecular subgroup. Like ALK (anaplastic lymphoma kinase) rearrangements in NSCLC, ROS1 fusions confer sensitivity to the inhibitor crizotinib. Crizotinib, which is a tyrosine kinase inhibitor (TKI), has been shown to be effective in tumors in several retrospective studies.

Recently the FDA approved entrectinib for the treatment of patients with ROS1-positive metastatic NSCLC. This indication is based on the results of pooled data from several trials. Together, these studies demonstrate the efficacy for entrectinib across a variety of solid tumor types including NSCLC with ROS1 fusion.

However, despite the efficacy of crizotinib or entrectinib in ROS1-positive NSCLC, patients will develop resistance to these tyrosine kinase inhibitors.

Lorlatinib is a new and potent ROS1 / ALK inhibitor optimized to penetrate the blood-brain barrier. A recent study has investigated the activity of lorlatinib against the crizotinib-resistant ROS1G2032R mutation. In this situation, lorlatinib effectively inhibited the catalytic activity of recombinant ROS1G2032R resulting in an antiproliferative response. Because of its potency as an ROS1 inhibitor and its ability to suppress the resistant ROS1 mutations, lorlatinib could be a treatment of choice in ROS1-positive NSCLC.

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

A Phase II Single-group Assignment, Multicenter Study of Efficacy and Safety of Lorlatinib Monotherapy After Failure of First-line Tyrosine Kinase Inhibitor in Patients With Advanced ROS1-positive Non-small Cell Lung Cancer (ALBATROS)

ORR is defined as the percentage of subjects with a confirmed complete response (CR) or partial response (PR) as per RECIST v1.1 criteria.

Percentage of subjects with a confirmed at 16 weeks complete response (CR) or partial response (PR) as per RECIST v1.1 criteria.

Time between the date of inclusion and the first date of documented disease progression (according to RECIST v1.1) or death (from any cause)

Time from the date of inclusion to the earliest date of disease progression (according to RECIST v1.1.)

Proportion of patients have achieved a confirmed best overall response of CR, PR or SD (Stable Disease) (according to RECIST v1.1.)

Time from the date of the first documented response (CR or PR) to the earliest date of disease progression or death due to any cause.

Time from the date of first dose of study drug to the date of death due to any cause

ORR estimated in patients with measurable CNS metastases at baseline.

DOR estimated in patients with measurable CNS metastases at baseline.

In patients without brain metastases baseline.

Intergroupe Francophone de Cancerologie Thoracique

Spots Global Cancer Trial Database for albatros

Every month we try and update this database with for albatros cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for albatros

Every month we try and update this database with for albatros cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for albatros cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.